Neuropace Stock

Neuropace EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Neuropace (NPCE) as of Aug 10, 2026 is -29.80. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -23.46 — a change of 27.00% (lower).

EV/EBIT

-29.80

YoY

27.00%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Neuropace is 2026 -29.80 . EV/EBIT (Enterprise Value to EBIT) of Neuropace was 2025 -23.46 . It decreases by 27.00% lower compared to the previous year.

The Neuropace EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
-5.37 base
Jan 1, 2022
-0.57 base
Jan 1, 2023
-6.15 base
Jan 1, 2024
-15.67 base
Jan 1, 2025
-30.03 base
Jan 1, 2026 (e)
-10.81 base
YEARPRICE-TO-EBIT
2026 est -10.81
2025 -30.03
2024 -15.67
2023 -6.15
2022 -0.57
2021 -5.37
2020 -
2019 -
Access this data via the Eulerpool API

Neuropace Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Neuropace's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Neuropace's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Neuropace's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Neuropace grows earnings faster than its peers.

Neuropace Stock analysis

What does Neuropace do? Neuropace Inc is a US-based company specializing in the development and manufacturing of medical devices. It is headquartered in Mountain View, California and has been operating since 2000. The company was founded as a spin-off from a study conducted by Dr. Martha Morrell at Stanford University, focusing on the treatment of epilepsy with implanted devices. Neuropace Inc's business model involves manufacturing and marketing medical devices for epilepsy treatment. These devices, known as neurostimulators, are implantable devices that send electrical impulses to the brain and can reduce epileptic seizures. The company has been involved in various areas of epilepsy treatment, including the development of devices for patients with pharmacoresistant focal epilepsies. These devices can be implanted in patients who do not respond to traditional treatments such as medications or surgeries. Neuropace Inc has also started focusing on the development of devices for epilepsy diagnosis. One of these devices is the ambulatory EEG monitor, which records brain activity and allows doctors to better detect epilepsy seizures. The company has launched a range of products to achieve its goal of enabling patients to have a better quality of life. The key product is the RNS neurostimulator, which is implanted in patients and continuously monitors brain activity using electrodes placed in the brain to monitor brain waves. When the neurostimulator detects unusual activity, it automatically sends impulses to the brain to prevent or reduce the occurrence of epileptic seizures. The benefit is that patients experience fewer seizures and can better organize and plan their daily lives. Neuropace Inc has a competitive position in the market with its products for treating pharmacoresistant focal epilepsies. The RNS neurostimulator is the only device approved by the US Food and Drug Administration FDA capable of reducing critical neurological outcomes in epilepsy. The company also has a strong presence in the field of epilepsy diagnosis, particularly with the ambulatory EEG monitor. Neuropace Inc has also formed strategic partnerships with other companies to bring its technologies to the market. The company has formed alliances with Medtronic, among others, for the marketing and distribution of the RNS neurostimulator. Through these partnerships, Neuropace Inc has expanded its reach in the market and strengthened its relationships with leading companies in the industry. In summary, Neuropace Inc is a company specializing in the development and manufacturing of medical devices for epilepsy treatment. The company has expanded its technologies to cover a broader range of epilepsy conditions and has achieved a high level of success with its products. With solid partnerships and a strong commitment to epilepsy treatment, Neuropace Inc is expected to continue leading the market for medical devices. Neuropace is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Neuropace stock

EV/EBIT (Enterprise Value to EBIT) of Neuropace is -29.80 in 2026.

EV/EBIT (Enterprise Value to EBIT) of Neuropace changed from -23.46 to -29.80, representing a 27.00% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) Neuropace since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s Neuropace with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — Neuropace

All Key Metrics — Neuropace